The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma by unknown
RESEARCH Open Access
The combination therapy of high-intensity
focused ultrasound with radiotherapy in
locally advanced pancreatic carcinoma
Yu-Jiang Li, Gui-Lin Huang, Xu-Ling Sun, Xin-Chun Zhao and Zhi-Gang Li*
Abstract
Background: The aim of the present study is to evaluate the effectiveness of the combined application of high-
intensity focused ultrasound (HIFU) and radiotherapy in the treatment of locally advanced pancreatic carcinoma
(LAPC).
Methods: A total number of sixteen patients with LAPC started treatment beginning with HIFU and radiotherapy
1 week after the HIFU treatment. Evaluation of the effectiveness of treatment was performed using main clinical
symptoms, serum levels of CA-19-9, Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, and the
Kaplan-Meier method for estimating median overall survival (OS). The occurrence of adverse reactions was
recorded.
Results: The main clinical symptoms including abdominal pain and lower back pain were alleviated, and the mean
visual analog scale (VAS) pain score declined from 5.1 points to just 3.3 points immediately after the HIFU
treatment. The median pain relief time was 5.6 months after radiotherapy, serum CA-19-9 levels began to decrease
significantly 1 week after the HIFU treatment, from 102.1 to 60.8 U/ml, and the median continuous decline time
was 4.3 months after radiotherapy. Partial response (PR) was observed in seven of sixteen patients, with stable
disease (SD) in four patients, and progressive disease (PD) in the remaining five patients at 6 months after
radiotherapy. Serum levels of amylopsin and lipase were not elevated to abnormal levels. The median OS was
14 months. No serious adverse reactions occurred.
Conclusions: Treatment with both HIFU and radiotherapy can quickly improve symptoms and the quality of life
and prolong survival lengths. This combination might be a promising therapeutic treatment for patients with LAPC.
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Background
According to the National Comprehensive Cancer Network
(NCCN) guidelines, locally advanced pancreatic carcinoma
(LAPC) can be defined as unresectable tumors involving
the celiac axis and the superior mesenteric artery but that
do not include distant metastasis. LAPC patients make up
25 to 30 % of all pancreatic cancer cases at the time of diag-
nosis and are not suitable for surgical resection [1, 2]. The
median survival time for LAPC is 6 to 10 months [3, 4].
Serious abdominal pain is the most common presentation
of this disease, which severely affects the quality of life and
the survival periods of the patients. Currently, chemother-
apy and radiotherapy are the two main treatment options
for LAPC. Although chemotherapy using gemcitabine
(GEM) has recently become the standard systemic therapy,
this treatment is insufficient for LAPC because the clinical
benefit response of chemotherapy is only 23.8 % [5]. Fur-
thermore, a study has suggested that chemotherapy is not
very effective for pain relief and causes serious adverse
effects [6]. The use of radiotherapy for LAPC is limited
because peripancreatic organs such as the duodenum, liver,
stomach, and spinal cord have poor tolerance for radi-
ation, and, as a result, adequate radiation doses cannot be
delivered to the pancreatic carcinoma. Therefore, a study* Correspondence: lizhigang0705@sina.com
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proposes that if radiation therapy is to be used for patients
with LAPC, it is not recommended to be used alone [7].
High-intensity focused ultrasound (HIFU) therapy can
ablate various solid tumors with thermal effects produced
by ultrasound waves in a noninvasive manner. Several
studies have shown that HIFU can successfully and safely
ablate LAPC with over 80 % of the patients achieving pain
relief, and the overall survival of patients can reach as long
as 12.4 months [8–10]. HIFU can ablate the internal
structure of tumors and remove the bulk of the tumor
burden but can potentially leave behind a small residue
of the periphery of tumors. This may lead to recurrence
or metastasis, which can be effectively treated with ra-
diation. Therefore, it is worth studying if a combination
of HIFU and radiotherapy can provide an optimal
therapeutic effect. The purpose of this study was to
share our experience in treating LAPC with a combin-
ation of HIFU and radiotherapy.
Methods
Patients
A total number of 16 patients with LAPC were prospectively
enrolled from January 2013 to March 2014, and the study
protocol was approved by the Ethics Committee of First
Affiliated Hospital of Medical College of Shihezi University.
All patients were informed of the potential benefits and risks
of the therapy, and written informed consents were obtained.
The inclusion criteria were as follows: (1) LAPC was
confirmed pathologically through pancreatic biopsies and
computed tomography (CT) images or magnetic reson-
ance imaging (MRI), and no tumor metastasis was found;
(2) a single tumor located in the head or body of the pan-
creas; (3) Karnofsky Performance Status Scale (KPS) of
patients was above 80 points; (4) the patients had received
no prior treatments including chemotherapy or other
invasive treatments; (5) the patients experienced chronic
upper abdominal and upper back pain, and the visual ana-
log scale (VAS) was over 3 points; (6) the lesions were
more apparent through ultrasound imaging and did not
affect the surrounding organs at the preoperative location;
and (7) the patients had no uncontrolled, serious diseases
such as diabetes, hypertension, or heart disease.
Treatment
HIFU treatment
All patients were examined using enhanced CT or MRI
imaging before and after HIFU treatment. All patients
received intestinal cleaning with polyethylene glycol
electrolyte powder and cleansing enema and skin prepar-
ation including degreasing before the treatment. During
the procedures, the patients were given an intravenous
sedative (midazolam, 3 mg) and an analgesic (fentanyl,
200 μg) to relieve discomfort and to prevent voluntary
or involuntary bowel movements.
The patients were placed face down on a water sac
filled with degassed water on the treatment table with
transducers located at the bottom of the sac. The epigas-
trium was submerged in the degassed water, and a water
balloon was placed between the abdominal wall and the
transducers to push the stomach and the intestines into
the HIFU beam path. The organs surrounding the lesion
were displayed using real-time ultrasonographic imaging.
The HIFU treatment began from the deep end to the
shallow end of the thickest part of the tumor, slice by
slice using a total focal range of 5 to 10 mm. The thick-
ness of the sections was set to 5 mm, and the focus was
at least 1.0 cm away from the boundary of the tumor to
prevent damage to the surrounding normal tissue. The
treatment frequency was 0.8 MHz, the treatment power
was 300 W, and the radiation time of each treatment
point was 20 to 30 s. After treatment, a 24-h fast was
recommended to all patients, in order to protect the sur-
rounding stomach and intestines.
Radiotherapy treatment
Three-dimensional conformal radiotherapy was scheduled
for 1 week after HIFU treatment. An initial localization
was performed. The patient was placed in the supine pos-
ition and immobilized to the platform using a body mold.
Reference points were marked on the body mold, and
plain and enhanced CT scans (slice thickness of 2.5 mm)
were obtained from the location of interest. The CT im-
ages were transferred to a workstation, and treatment
plans were developed using a treatment planning system.
A medical linear accelerator (2100C/D) was purchased
from Varian Inc. (USA). Radiotherapy was delivered using
6 MV photons at 1.5 Gy per fraction, once a day for 5 days
a week, for a total dose of 45 Gy, with a required field re-
duction after 33 Gy.
Patient evaluation
VAS pain scores were recorded immediately after HIFU
treatment and every week thereafter until the pain pro-
gression, which was defined as the pain intensity or anal-
gesic requirements, returned to pre-treatment levels.
Amylopsin and lipase levels were measured immediately
and 1 week after HIFU treatment. Serum CA-19-9 levels
were measured 1 week after HIFU treatment and every
month thereafter until rise.
According to the Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines [11], complete response
(CR) was defined as the absence of all target lesions, a
partial response (PR) and progressive disease (PD) as a
greater than 30 % decrease and a greater than 20 % in-
crease in the sum of the longest diameters of the target
lesions, respectively, and stable disease (SD) as neither
PR nor PD.
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Pain relief time was defined as the time from the date
of alleviating pain after the completion of the treatment
to the first documentation of progressive pain or death.
Overall survival (OS) time was defined as the time from
the initial treatment to the death from any cause or the
date of the last follow-up.
Related adverse events such as burns, abdominal pain,
pancreatitis, jaundice, hemorrhage, gastrointestinal per-
foration, and intestinal necrosis were documented. The
degree of severity of adverse effects is based on the uni-
fied standardized Society of Interventional Radiology
(SIR) grading system [12].
Statistical analysis
All data were analyzed by using SPSS19.0 software (SPSS,
IBM Company, USA). The data are presented as the
mean ± SD for normally distributed data or medians for
non-normally distributed data. Independent sample t tests
and Mann-Whitney U tests were used for the analysis of
normally distributed data and non-normally distributed




The procedures were successfully performed on all pa-
tients. The average age of the patients was 62.3 years
old, and 62.5 % of them were male. Their KPS averaged
84.4 points on a 100-point scale, and the average VAS
pain score was 5.1 points. A majority of the tumors were
located at the head of the pancreas, while the others
were located in the body of the pancreas, and the mean
maximum diameter was 3.7 cm (Table 1).
The effectiveness of treatment
The effectiveness of treatment for all patients was evalu-
ated. The follow-up period was 6–17 months after treat-
ment. Three cases were lost to follow-up at 10, 11, and
13 months, and the remaining cases died within the
follow-up period. The mean ablation rate was
71.3 %(50.3–92.1 %) immediately after HIFU treatment,
which indicated tumor tissue necrosis, the rate of which
was measured using enhanced MRI, CT, or ultrasound.
VAS pain score declined from 5.1 points to just 3.3
points immediately after HIFU treatment. The median
duration of pain relief time was 5.6 months after the
radiotherapy. Pain was improved in the majority of pa-
tients; the total effective rate was 93.8 % (15/16). Serum
CA-19-9 levels began to fall significantly a week after
HIFU treatment, from 102.1 to 60.8 U/ml, and the
median continuous decline time was 4.3 months after
radiotherapy (Table 2). PR, SD, and PD rates were 43.5,
25, and 31.3 %, respectively, at 6 months after radiother-
apy (Table 2). OS is shown in Fig. 1, and the median sur-
vival time of patients was 14.0 months.
Adverse effects
There were no differences in the serum levels of amy-
lopsin and lipase before and after the HIFU treatment
(Tables 1 and 2), and none of the patients developed
clinical pancreatitis. HIFU treatment-related adverse
reactions such as burns, bleeding, infections, gastro-
intestinal tract perforation, and tumor hemorrhage
were not observed in all patients. During radiotherapy
and within the first 4 weeks after radiotherapy, three
patients (18.8 %) experienced grade A–B adverse events
including fatigue, nausea, and abdominal distension,
which were treated without hospitalization. Two
patients (12.5 %) experienced gastrointestinal ulcers, a
grade C adverse event, and needed hospital care
(Table 2). There were no other serious adverse events
related to HIFU treatment and radiotherapy during the
follow-up period.
Discussion
Approximately 73 % of patients with pancreatic carcin-
oma presented serious pain [13], and it severely affected
the quality of life and the survival rate of the patients;
previous studies [14] had shown that pain was an inde-
pendent prognostic factor for the overall survival.
Current therapeutic methods such as chemotherapy and
radiotherapy are usually offered to patients and are often
ineffective at relieving pain. Research shows that the
median survival time could be as long as 11 months
after radiotherapy alone [15], but remission rates of pain
induced by pancreatic carcinoma are only approximately
29 % with radiotherapy monotherapy [6]. Moreover,
severe and acute radiotherapy-related toxicities are






Age (year) 62.3 ± 10.5 (49–72)
Karnofsky performance status 84.4 ± 5.1 (80–90)




Tumor diameter (cm) 3.7 ± 2.6 (3.0–6.2)
Serum CA-199 pre-HIFU (U/L) 102.1 (25.8–229.6)
Serum amylopsin and lipase
pre-HIFU (U/L)
101.5 (49.3–202.6)/210.5 (73.7–401.1)
Visual analog scale(VAS) 5.1 ± 2.2 (3–8)
a BMI Body mass index
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relatively common, including severe enteritis, ulceration,
and perforation of gastrointestinal tract [16]. In some re-
cent years, other techniques such as radiofrequency,
cryoablation, microwave, and electroporation had been
applied to the treatment of LAPC. Despite a 50–100 %
remission rates of pain, but as most of treatment
methods were performed during operation, the mortality
and other adverse reactions increased significantly [17].
HIFU is a new, noninvasive technology and holds prom-
ise in the field of pancreatic cancer treatment. Numer-
ous studies have confirmed the safety and effectiveness
of HIFU treatment for LAPC [10, 18, 19], especially in
providing pain relief after treatment. Along with its
unique advantages, the total remission rate of pain with
HIFU treatment was 87.5 to 100 % [8, 20]. In addition,
HIFU as a thermotherapy might be an effective way of
augmenting radiation therapy [21]. Given the above data,
the combination therapy of HIFU with radiotherapy for
LAPC might have good therapeutic effects in clinical
practice.
In our subjects, the combined application of HIFU
and radiotherapy significantly relieved pain in most pa-
tients and had longer remission durations compared to
simple HIFU, which only resulted in a 10-week remis-
sion [20]. The causes for pain relief after HIFU treat-
ment are not fully understood, but researchers have
proposed the following mechanisms [6, 22, 23]: (1) the
thermal effects of HIFU might damage the nerve fibers
which were infiltrated by the tumor; (2) the solar plexus
in the target area might be damaged by a long ultrasonic
radiation in the far field and caused the pain signal to
the brain to be blocked; (3) the pressure within the
tumor decreased after treatment causing the pressure on
the nerve to be reduced; and (4) HIFU may also result in
acoustic pressure and cavitation-driven changes in ion
flux through both existing ion channels and defects
formed in the neuronal membrane. The experimental
results proved that HIFU can induce transient neuromo-
dulation and resulted in changes to the neuronal excita-
tion levels. Moreover, radiotherapy provided a good local
control for LAPC and helped patients have a longer
pain-free period. In this study, one patient’s pain was not
alleviated after HIFU treatment, and we suspect that it
might be related to a low ablation rate. Pain control is
an important aspect of LAPC treatment; it can signifi-
cantly improve quality of life and prolong the patients’
lifespan. This study confirms both of these aspects
regarding HIFU treatment.
HIFU can prolong the survival period of the patient.
Previous research has shown that, with HIFU treatment,
17.5 % of cases of primary tumors experienced PR, and
70 % of the cases experienced SD, and the overall
median survival periods were 10 and 12.4 months,
respectively [10, 20]. Thus, HIFU has an advantage over
either radiotherapy or chemotherapy alone [15, 24]. In our
study, the PR and SD were 43.5 and 25 %, respectively,
and the overall median survival period was 14 months.
The combination of HIFU and radiotherapy has obvious
advantages, including simple treatment, higher PR rate,
and prolongation of survival, which are similar to chemo-
radiation [25, 26]. The levels of tumor marker CA-19-9
decreased in patients after treatment and remained at
lower levels for a long time, which indicates that LAPC
was controlled well.
In terms of the adverse reactions, the combined ther-
apy decreased the dose of external irradiation, so the
radiation-related complications were reduced and com-
parable to those of simple radiotherapy. No serious
adverse reactions occurred during or after the combined
application of HIFU and radiotherapy in this study.
Compared with chemoradiation, toxicity and the treat-
ment cycle were greatly reduced [25, 26]. Serum levels
Table 2 Treatment results of tumor
Variable Value












The median overall survival (OS) time (month) 14 (8.0–15.5)
Incidences of adverse event (SIRC) (%) 12.5 (2/16)
Fig 1 The Kaplan-Meier survival curve of all 16 patients. The median
overall survival (OS) time was 14 months (95 % CI 8.0–15.5)
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of amylopsin and lipase did not increase in the study,
which suggests that HIFU treatment does not cause pan-
creatic inflammation.
There are also limitations of the research. Although the
safety and efficiency of the technique were encouraging,
our results came from retrospective, single institutional,
uncontrolled, non-blinded, small study. In the future, we
needed larger trials with top-level design not only to fur-
ther delineate the efficiency of the technique but to delin-
eate rarer adverse events that smaller trials might not have
been adequately powered to show.
Conclusions
In conclusion, our results demonstrated that the com-
bined application of HIFU and radiotherapy might be a
promising therapeutic treatment to patients with LAPC.
However, the clinical efficacy of this combination ther-
apy needs to be evaluated using double-blind, random-
ized controlled trials.
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